**Supplementary Table 1**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Tumor** | | |  | **Plasma** | | |
| **Cytokine** | **FLTK-/-** | **WT** | **Change (%)** |  | **FLTK-/-** | **WT** | **Change (%)** |
| **IFN-γ** | 2.9 (0.7) | 2.4 (0.8) | 🡵22% |  | 0.4 (0.05) | 0.7 (0.2) | 🡶36% |
| **IL-10** | 4.1  (0.4) | 5.3 (0.6) | 🡶23% |  | 15.1 (1.8) | 20.4 (3.2) | 🡶26% |
| **IL-12** | 31.5 (3.2) | 43.4  (4.9) | 🡶27% |  | 23.5 (3.7) | 19.8 (2.8) | 🡵19% |
| **IL-1β** | 20.7 (5.2) | 53.7 (9.7) | 🡶43% |  | 0.4 (0.05) | 1.3 (0.3) | 🡶68% |
| ***IL-2*** | 1.6 (0.2) | 1.9 (0.3) | 🡶15% |  | 1.4 (0.2) | 1.3  (0.4) | 🡶39% |
| ***IL-4*** | 0.6 (0.1) | 0.8 (0.1) | 🡶29% |  | 0.5 (0.05) | 0.4 (0.05) | 🡵30% |
| ***IL-5*** | 0.2 (0.01) | 0.3 (0.03) | 🡶31% |  | 1.5 (0.4) | 1.7 (0.3) | 🡶10% |
| **IL-6** | 82.9 (8.3) | 124 (27.8) | 🡵12% |  | 49.7 (15.6) | 48.8 (12.6) | 🡵2% |
| **CXCL-1** | 177.8 (12.5) | 112.3 (12.7) | 🡵10% |  | 168.2  (33) | 217.3 (32.1) | 🡶23% |
| **TNF-α** | 9.1  (1.2) | 8.4 (1.4) | 🡵8.5% |  | 6.9 (0.75) | 10.9 (2.3) | 🡶37% |

**Footnote:** Values represent the protein concentration (pg per mg of tissue protein) in *Flt1*TK–/– vs. WT in PAN02 bearing obese mice, followed by the percentage of change. Bold numbers highlighted in grey represent significant differences (P < 0.05), bold numbers not highlight represent trends. Standard errors of the mean are found in parentheses. Of note, the cytokine expression in tumors of some cytokines presented in this table is also depicted in the form of a bar graph in Figure 3D.

**Supplementary Table 2**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cytokine** | **Lean** | | **Lean TK (-/-)** | | **Obese** | | **Obese TK(-/-)** | |
|  | **Average** | **SEM** | **Average** | **SEM** | **Average** | **SEM** | **Average** | **SEM** |
| **IL-1β+** | 70.6 | 1.0 | 64.5 | 7.7 | 80.1 | 5.1 | 71.3 | 4.1 |
| **VEGFR-1+** | 49.1 | 9.9 | 60.4 | 6.2 | 54.0 | 6.0 | 49.9 | 5.9 |
| **IL-1β+/VEGFR-1-** | 30.5 | 7.9 | 18.8 | 5.5 | 31.0 | 9.9 | 25.2 | 3.8 |
| **IL-1β-/VEGFR-1+** | 9.0 | 2.9 | 14.7 | 4.4 | 4.9 | 2.3 | 5.5 | 0.5 |
| **Double +** | 40.1 | 7.5 | 45.7 | 6.4 | 49.1 | 6.3 | 46.2 | 6.8 |
| **% of VEGFR-1+ TAMs expressing IL-1β** | 82.3 | 4.0 | 75.5 | 7.3 | 91.8 | 3.0 | 88.2 | 2.2 |
| **% of IL-1β+ TAMs expressing VEGFR-1** | 56.9 | 11.0 | 72.0 | 6.6 | 62.2 | 10.1 | 54.2 | 10.5 |

**Footnote:** Quantifications of the expression of: total IL-1ß in F4/80+ TAMs (percentage); total VEGFR-1 in F4/80+ TAMs; IL-1ß positive and VEGFR-1 negative in F4/80+ TAMs; VEGFR-1 positive and IL-1ß negative in F4/80+ TAMs; both IL-1ß/VEGFR-1 in F4/80+ TAMs; percentage of VEGFR-1 positive TAMs that co-express IL-1ß, percentage of IL-1ß positive TAMs that co-express VEGFR-1 (n = 3-8 tumors/group). Of note, total VEGFR-1 in F4/80+ TAMs and the percentage of VEGFR-1 positive TAMs that co-express IL-1ß presented in this table is also depicted in the form of a bar graph in Supplementary Figure 3Aii. Statistical analysis did not produce significant differences between groups.